News | April 11, 2013

Society of Nuclear Medicine Celebrates 60th Annual Meeting

Meeting highlights nuclear medicine and molecular imaging advances from bench to bedside

April 11, 2013 — An estimated 5,000 nuclear medicine and molecular imaging professionals are expected to gather in June for the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to discuss the latest advances in radiotracers, imaging modalities, radionuclide therapies and quality.

The meeting will be held June 8-12 in Vancouver, British Columbia, Canada. This year’s meeting marks the 60th anniversary of the SNMMI Annual Meeting.

“Our first meeting was held in Seattle, Wash., in 1954, and was reported to have had 109 attendees who heard 13 scientific presentations and one panel discussion,” said Peter Herscovitch, M.D., chair of SNM’s Scientific Program Committee (SPC).  

Today, the SNMMI Annual Meeting offers education opportunities for physicians, technologists, pharmacists, physicists, scientists and laboratory professionals in the nuclear medicine and molecular imaging fields. More than 110 expert-led continuing education sessions will be held on topics including emerging PET radiotracers, dementia, neuroendocrine tumor imaging, novel targeted radiopharmaceutical therapies and hybrid imaging. Several other special courses will be held, including 11 categorical sessions, 22 self-assessment modules, a two-day CT case review workshop and a new Education Forum designed specifically for nuclear medicine program directors. The Annual Meeting will also feature a special session honoring Henry N. Wagner, Jr., M.D., nuclear medicine pioneer and visionary, who died last year.

SNMMI will again offer its Virtual Meeting for those who missed sessions of interest at the meeting or those unable to travel to Vancouver. The Virtual Meeting will include 70 of the most popular sessions, captured on video and available to view online or on a mobile device.

For more information: www.snmmi.org/am2013

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
ASTRO and ASCO Launch New Cancer Care Quality Registry
News | Radiation Therapy | January 22, 2018
January 22, 2018 — A registry that tracks the quality of medical care provided to patients receiving cancer treatment
First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Overlay Init